News
CDXC
--
0.00%
--
ChromaDex Shares Preclinical Research Findings And Scientific Initiations From The ChromaDex External Research Program
ChromaDex Corp. (NASDAQ:CDXC) today announced findings from recently published preclinical studies, as well as recently registered clinical research, investigating Niagen® (patented nicotinamide riboside, or
Benzinga · 5d ago
ChromaDex Shares Preclinical Research Findings and Scientific Initiations from the ChromaDex External Research Program (CERP™)
LOS ANGELES, September 20, 2021--ChromaDex Corp. (NASDAQ:CDXC) today announced findings from recently published preclinical studies, as well as recently registered clinical research, investigating Niagen® (patented nicotinamide riboside, or "NR") in variou...
Business Wire · 5d ago
Chromadex Says Niagen Supplement Shows Potential Against Glaucoma, Alzheimer's Disease in Preclinical Trials
MT Newswires · 5d ago
Hot Stocks: MSFT gives to shareholders; ADP CFO departure; SKIL earnings; CDXC legal setback; HUT raising capital
Microsoft (NASDAQ:MSFT) represented the biggest name making news in Wednesday's pre-market period. Shares of the software giant edged up as the company enhanced its plan to return cash to shareholders.
Seekingalpha · 09/15 12:53
Why Are ChromaDex Shares Trading Lower On Wednesday?
Benzinga · 09/15 12:37
Melco Resorts & Entertainment, Hut 8 Mining, Theravance Biopharma among premarket losers' pack
Nuwellis (NASDAQ:NUWE) -28% after proposes stock offering Theravance Biopharma (NASDAQ:TBPH) -20% after ampreloxetine misses primary endpoint in late-stage orthostatic; on headcount cut to focus on respiratory disease portfolio hypotension study DAVIDsTEA ...
Seekingalpha · 09/15 12:26
Should You Think About Buying ChromaDex Corporation (NASDAQ:CDXC) Now?
ChromaDex Corporation ( NASDAQ:CDXC ), is not the largest company out there, but it saw significant share price...
Simply Wall St. · 09/09 10:33
Return on Capital Employed Insights for ChromaDex
After pulling data from Benzinga Pro it seems like during Q2, ChromaDex's (NASDAQ:CDXC) reported sales totaled $17.70 million. Despite a 24.56% in earnings, the company posted a loss of $5.55 million.
Benzinga · 08/20 17:41
Investors in ChromaDex (NASDAQ:CDXC) have made a solid return of 118% over the past five years
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
Simply Wall St. · 08/10 05:22
HC Wainwright & Co. Maintains Buy on ChromaDex, Raises Price Target to $12
HC Wainwright & Co. analyst Raghuram Selvaraju maintains ChromaDex (NASDAQ:CDXC) with a Buy and raises the price target from $11 to $12.
Benzinga · 08/04 10:38
--B. Riley Lowers ChromaDex's PT to $16 from $18 After 'Roughly In Line' Q2 Metrics, Keeps Buy Rating
MT Newswires · 08/04 09:28
ChromaDex (CDXC) Reports Q2 Loss, Tops Revenue Estimates
Zacks.com · 08/03 21:25
ChromaDex EPS in-line, beats on revenue
ChromaDex (NASDAQ:CDXC): Q2 GAAP EPS of -$0.08 in-line. Revenue of $17.7M (+15.7% Y/Y) beats by $0.34M. Shares -1.5%. Press Release
Seekingalpha · 08/03 20:36
BRIEF-ChromaDex Reports Q2 Loss Per Share Of $0.08
reuters.com · 08/03 20:09
ChromaDex Corporation Reports Second Quarter 2021 Financial Results
ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2021.
Business Wire · 08/03 20:02
-- Earnings Flash (CDXC) CHROMADEX CORPORATION Reports Q2 Revenue $17.7M, vs. Street Est of $17.4M
MT Newswires · 08/03 16:08
Analysts Estimate ChromaDex (CDXC) to Report a Decline in Earnings: What to Look Out for
Zacks.com · 07/27 19:02
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Benzinga · 07/23 12:10
ChromaDex Corporation's (NASDAQ:CDXC) Intrinsic Value Is Potentially 27% Above Its Share Price
How far off is ChromaDex Corporation ( NASDAQ:CDXC ) from its intrinsic value? Using the most recent financial data...
Simply Wall St. · 07/11 08:11
ChromaDex rises after NIAGEN-component shows promise in COVID-19 trial
Ilya S. Savenok/Getty Images Entertainment ChromaDex ([[CDXC]] +8.6%) has added nearly a tenth by afternoon trading after a Phase 3 clinical trial showed that a mix of metabolic activators including
Seekingalpha · 06/28 18:06
Webull provides a variety of real-time CDXC stock news. You can receive the latest news about ChromaDex through multiple platforms. This information may help you make smarter investment decisions.
About CDXC
Chromadex Corporation is an integrated nutraceutical company. The Company and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provides research and quality-control products and services to the natural products industry. The Company partners with universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of nicotinamide adenine dinucleotide (NAD) and its impact on human health. The Company’s operated segments are: Consumer Product, Ingredients, and Analytical Reference Standards and Service Segment. Its Consumer Product segment offers TRU NIAGEN to consumers worldwide. Its ingredients business segment develops and commercializes ingredients, including nicotinamide riboside (NR), for which its brand name is NIAGEN. It also develops pterostilbene, which is marketed and sold under its brand name, pTeroPure.